A Phase 2/3 interventional study of Vaginal DHEA and Placebo in Vaginal Dryness, Breast Cancer and Urinary Incontinence, sponsored by Hadassah Medical Organization. Withdrawn at 1 site in Israel. Open to female participants aged 35 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-11-28.
Sponsored by Hadassah Medical Organization · Phase 2/3, Interventional, and Treatment
There does not appear to be a consensus regarding the treatment of vaginal dryness in women who have a contraindication to the use of estrogen products. DHEA, when used locally, may improve the symptoms of vaginal dryness due to its chemical properties.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
Browse Breast Neoplasms studies →Hadassah Medical Organization is the lead sponsor of 659 studies on the registry; 54 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Vaginal DHEA 0.5%(6.5mg)inserted nightly
Drug: Vaginal DHEA
Drug: Placebo
improvement in vaginal dryness
Time frame: 12 weeks
improvement in urinary incontinence
Time frame: 12 weeks
improvement in sexual satisfaction
Time frame: 12 weeks
This study is withdrawn, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hadassah Medical Organization